Scarica l'app Stockscreener
29.20
4.82%
-1.48
Dopo l'orario di chiusura:
29.20
Precedente Chiudi:
$30.68
Aprire:
$30.2
Volume 24 ore:
68,374
Relative Volume:
2.27
Capitalizzazione di mercato:
$29.70M
Reddito:
-
Utile/perdita netta:
$-33.04M
Rapporto P/E:
-3.208
EPS:
-9.1023
Flusso di cassa netto:
$-39.66M
1 W Prestazione:
-5.81%
1M Prestazione:
-9.18%
6M Prestazione:
+47.47%
1 anno Prestazione:
-91.10%
Intervallo 1D:
$29.20
$31.06
Intervallo di 1 settimana:
$26.45
$32.59
Portata 52W:
$15.10
$909.98
Quince Therapeutics Inc Stock (QNCX) Company Profile
Nome
Quince Therapeutics Inc
Settore
Industria
Telefono
415-910-5717
Indirizzo
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
29.20 | 31.53M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-08-05 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-03-24 | Iniziato | Oppenheimer | Outperform |
Quince Therapeutics Inc Borsa (QNCX) Ultime notizie
Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX) - The Globe and Mail
LifeSci Capital Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Maintains Target Price $98 - Moomoo
Citizens reiterates Quince Therapeutics stock rating on therapy potential - Investing.com
Quince Therapeutics forms Scientific Advisory Board to advance LAM-001 - scanx.trade
Quince Therapeutics Price Target Announced at $70.00/Share by Rodman & Renshaw - Moomoo
Rodman & Renshaw initiates Quince Therapeutics stock with buy rating - Investing.com
Rodman & Renshaw initiates Quince Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Quince Therapeutics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (QNCX) - Traders Union
Quince Therapeutics, Inc. (QNCX) Earnings Date, Reports and Estimates - Traders Union
Live Quince Therapeutics, Inc. (QNCX) Technical Analysis - Traders Union
Quince Therapeutics, Inc. (QNCX) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Quince Therapeutics stock falls 3.83 percent on Nasdaq - AD HOC NEWS
QNCX Upgraded by Citizens -- Price Target Announced at $77.00 - GuruFocus
Citizens JMP Upgrades Quince Therapeutics(QNCX.US) to Buy Rating, Announces Target Price $77 - Moomoo
Citizens upgrades Quince Therapeutics stock rating on rare disease pipeline By Investing.com - Investing.com Australia
Citizens upgrades Quince Therapeutics stock rating on rare disease pipeline - Investing.com
Quince Therapeutics, Inc. (QNCX) Stock Price History & Data - Traders Union
QNCX Should I Buy - Intellectia AI
Quince Therapeutics stock prepares for LAM-001 KOL event as shares trade below recent highs - AD HOC NEWS
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026 - Yahoo Finance
Quince Therapeutics, Inc.Common Stock (Nasdaq:QNCX) Stock Quote - The Chronicle-Journal
Quince Therapeutics Divests Italian Subsidiary, Refocuses Strategy - TipRanks
Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction By Investing.com - Investing.com South Africa
Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction - Investing.com India
Quince Therapeutics Faces Nasdaq Listing Compliance Challenges - The Globe and Mail
Quince Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Quince Therapeutics to Participate in September 2026 Investor Conferences - Quiver Quantitative
$Quince Therapeutics (QNCX.US)$ - Moomoo
QNCX stock holds steady as Quince Therapeutics pursues strategic alternatives - ad-hoc-news.de
Quince Therapeutics Announces Planned Presidential Leadership Transition - The Globe and Mail
Quince Therapeutics' Charles Ryan to Depart as President, Last Day Sept 8, 2026 - TradingView
Quince Therapeutics, Inc. Announces Resignation of Charles Ryan from President, Effective September 8, 2026 - marketscreener.com
Quince Therapeutics, Inc. SEC Filing (Aug 25, 2026) - Stock Titan
Craig-Hallum Initiates Quince Therapeutics at Buy With $68 Price Target - Yahoo Finance
Quince (QNCX) Results at a Glance: The Available Earnings Metric Delivers a Beat; Market Move: Shares Finish 7.12% Lower in the Available RecordEarnings Seasonality - vinanet.vn
Balyasny Asset Management L.P. Initiates New Position in Quince Therapeutics Inc (QNCX) - GuruFocus
Craig-Hallum Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $68 - Moomoo
Quince (QNCX) Chart: Slides 0.90% to $34.26 at the Close; Price Setup: Price Remains Between $32.55 Support and $35.97 Resistance in the Available RecordSentiment Divergence - vinanet.vn
Craig-Hallum Initiates Coverage on Quince Therapeutics (QNCX) wi - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
LifeSci Capital Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Cuts Target Price to $98 - Moomoo
Quince Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
QNCX Reiterated by Cantor Fitzgerald -- Price Target Maintained at $70 - gurufocus.com
Quince Plans Shareholder Vote on Major Stock Issuance - The Globe and Mail
Form 8K Quince Therapeutics Inc For: 17 August By Investing.com - Investing.com Nigeria
Quince Therapeutics Closes Orphai Acquisition With $115M PIPE Financing - Minichart
Quince Therapeutics plans special meeting to vote on share issuance and potential change of control - Investing.com
Quince Therapeutics to seek shareholder OK for Series C conversion, adding ~11M shares and reclassifying $6.3M warrants - TradingView
Ikarian Capital discloses 9.0% Quince Therapeutics (QNCX) ownership in Schedule 13G - Stock Titan
Nantahala Capital (QNCX) reports 0% stake in Quince Therapeutics in latest 13G/A - Stock Titan
Quince Therapeutics (QNCX) Jumps 5% to $34.04 as Bulls Target $35.74 ResistanceBlue Chip Entry Points - vinanet.vn
Quince Therapeutics Inc Azioni (QNCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Quince Therapeutics Inc Azioni (QNCX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):